发布时间:2021/8/13 15:49:12 阅读人数:631
氨基酸重复扩增发生在 >20 种遗传性人类疾病中,许多发生在转录因子 (TFs) 的固有无序结构域 (IDRs)。此类疾病与蛋白质聚集有关,但聚集物对病理的作用一直存在争议。该研究报道了转录因子 HOXD13 (导致人类遗传性多指症) 中,丙氨酸的重复扩增改变了其相分离能力及与转录共激活因子共凝聚的能力。在体外和体内,HOXD13 重复扩增扰乱了含 HOXD13 凝结物的成分,并且在小鼠多指模型中以细胞特异性方式改变了转录程序。同样的,其他 TFs (HOXA13, RUNX2 和 TBP) 中与疾病相关的重复扩增也改变了其相分离。这些结果表明,转录凝聚物的非融合可能是对应疾病的病理基础。研究人员提出了 TF IDRs 的分子分类,这为转录失调相关疾病中的 TF 功能的研究提供了架构。
Distinct Processing of lncRNAs Contributes toNon-conserved Functions in Stem Cells
This study reports that at an equivalent of approximately one-tenth the clinical dose for HCC, sorafenib treatment effectively prevents the progression of NASH in both mice and monkeys without any observed significant adverse events. Mechanistically, sorafenib's benefit in NASH is independent of its canonical kinase targets in HCC, but involves the induction of mild mitochondrial uncoupling and subsequent activation of AMP-activated protein kinase (AMPK). Collectively, our findings demonstrate a previously unappreciated therapeutic effect and signaling mechanism of low-dose sorafenib treatment in NASH. The researchers envision that this new therapeutic strategy for NASH has the potential to translate into a beneficial anti-NASH therapy with fewer adverse events than is observed in the drug's current use in HCC.
Y-27632 (dihydrochloride), AP20187 purchased from MCE.
结直肠癌 (CRCs) 由不同基因型和表型的细胞混合组成。该研究首次揭示了 CRC 细胞生物合成能力的异质性。研究人员发现 CRCs 中的大部分核糖体 DNA 转录和蛋白质合成发生在特定的有限肿瘤细胞亚群中。其余的肿瘤细胞由于分化而发生了不可逆的生物合成能力丧失。生物合成区域内的癌细胞的 RNA 聚合酶 I 亚基 A (POLR1A) 水平升高。POLR1A 高水平细胞群体的遗传消融对 CRCs 造成不可逆的生长停滞。研究显示,升高的生物合成决定了 LGR5+ 和 LGR5- 肿瘤细胞的干细胞特性。因此,CRCs 是基于转录核糖体 DNA 和合成蛋白质的差异能力的简单的细胞层次结构。
The study reveals a previously unappreciated heterogeneity in the biosynthetic capacities of CRC cells. The researchers discovered that the majority of ribosomal DNA transcription and protein synthesis in CRCsoccurs in a limited subset of tumor cells that localize in defined niches. The rest of the tumor cells undergo an irreversible loss of their biosynthetic capacities as a consequence of differentiation. Cancer cells within the biosynthetic domains are characterized by elevated levels of the RNA polymerase I subunit A (POLR1A). Genetic ablation of POLR1A-high cell population imposes an irreversible growth arrest on CRCs. This research shows that elevated biosynthesis defines stemness in both LGR5+ and LGR5- tumor cells. Therefore, a common architecture in CRCs is a simple cell hierarchy based on the differential capacity to transcribe ribosomal DNA and synthesize proteins.
Seliciclib, THZ531, LDC000067 purchased from MCE.
分子胶化合物能诱导蛋白质-蛋白质相互作用,在存在泛素连接酶的情况下导致蛋白质降解。与传统的酶抑制剂不同,这些分子胶降解剂在亚化学计量起催化作用,快速降解其靶标。在该研究中,研究人员通过系统地挖掘数据库以研究 4,518 种临床和临床前小分子的细胞毒性与数百种人类癌细胞系中 E3 连接酶成分表达水平的相关性,鉴定了一种 CDK 抑制剂 CR8 作为分子胶降解剂。该研究表明,暴露在表面的部分的化学变化使抑制剂获得分子胶功能,因此,研究人员认为这可以作为更广泛的策略,将目标结合分子转化为分子胶。
Remdesivir purchased from MCE.
This study shows the full functionality of a yeast-based synthetic genomics platform to genetically reconstruct diverse RNA viruses, including members of the Coronaviridae, Flaviviridae and Paramyxoviridae families. Viral subgenomic fragments were generated using viral isolates, cloned viral DNA, clinical samples, or synthetic DNA, and reassembled in one step in Saccharomyces cerevisiae using transformation associated recombination (TAR) cloning to maintain the genome as a yeast artificial chromosome (YAC). T7-RNA polymerase has been used to generate infectious RNA to rescue viable virus. Based on this platform we have been able to engineer and resurrect chemically-synthetized clones of the recent epidemic SARS-CoV-2 in only a week after receipt of the synthetic DNA fragments. The technical advance we describe here allows a rapidly response to emerging viruses as it enables the generation and functional characterization of evolving RNA virus variants-in real-time-during an outbreak.
尽管有证据表明骨髓增生异常综合症 (MDS) 中存在慢性炎症, MDS 造血干细胞和祖细胞 (HSPC) 中 Toll 样受体 (TLR) 信号调节异常,但 MDS HSPC 在炎症环境中比正常 HSPC 更具有竞争优势的机制尚不清楚。该研究发现,慢性炎症是 MDS HSPC 竞争优势和疾病进展的决定因素。与正常 HSPC 相比,涉及通过非经典 NF-κB 途径信号传导的 MDS HSPC 细胞内源性反应,保护了这些细胞免于慢性炎症。为了响应炎症,MDS HSPC 由经典的 NF-κB 信号转为非经典的 NF-κB 信号,这一过程依赖于 TLR-TRAF6 介导的 A20 激活。通过敲除 A20 或抑制非经典 NF-κB 途径,TLR-TRAF6 诱导的 HSPC 的竞争优势消失。这些发现揭示了 MDS HSPCs 克隆优势的机制基础,并表明干扰非经典 NF-κB 信号传导可以抑制 MDS 的进展。
Remdesivir purchased from MCE.
由 SARS-CoV-2 引起的 COVID-19 大流行已成为全球性危机。SARS-CoV-2 的复制需要病毒 RNA 依赖性的 RNA 聚合酶 (RdRp),它是抗病毒药物 Remdesivir 的靶标。该研究报道了 SARS-CoV-2 RdRp 的两种冷冻电子显微镜结构: 2.8Å 的分辨率下呈 apo 形式 (apo form),和 2.5Å 的分辨率下的 50 个碱基的模板引物 RNA 和 Remdesivir 形成的复合体。复杂的结构揭示了部分双链 RNA 模板插入了 RdRp 的中心通道,Remdesivir 在个复制的碱基对处共价掺入引物链,并终止了链延长。该研究为抗病毒感染的药物研发提供了重要的理论机制和结构基础。
This study reports the cryo-EM structure of the SARS-CoV-2 RdRp either in the apo format 2.8 Å resolution or in complex with a 50-base template-primer RNA and Remdesivir at 2.5 Å resolution. The complex structure reveals that the partial double-stranded RNA template is inserted into the central channel of the RdRp where Remdesivir is covalently incorporated into the primer strand at the first replicated base pair and terminates chain elongation. Our structures provide critical insights into the mechanism of viral RNA replication and a rational template for drug design to combat the viral infection.
相关产品